Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Partners in Advancing Rheumatology

James O’Dell, MD, and David I. Daikh, MD, PhD  |  Issue: August 2012  |  August 8, 2012

Dr. O'Dell
Dr. O’Dell

Dr. O'Dell
Dr. Daikh

One of the major goals of the ACR is to promote basic, translational, clinical, and health-services research aimed at improving the health of patients with rheumatic diseases. The ACR supports research and education through its annual meetings and clinical symposia, publication of its journals—Arthritis & Rheumatism and Arthritis Care & Research—advocacy to increase funding of rheumatology research, and a strong collaboration with our own Research and Education Foundation (REF).

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The REF supports the overall research goals of the ACR on several fronts. It provides a robust portfolio of awards and grants to address critical shortfalls in the overall rheumatology landscape. The REF also promotes mentorship activities through efforts such as the REF Investigators’ Meeting, held in conjunction with the ACR Rheumatology Research Workshop, which brings junior and senior investigators together for mentorship opportunities. In conjunction with the National Institutes of Health, the REF leads discussions about how to best develop the careers of physician–scientists involved in rheumatic disease research.

Great Strides in Research Support

The ACR supports the goals of the Foundation as well. During Dr. O’Dell’s time as the REF president in 2006–2008, the ACR was generous in its support by becoming the first $5-million donor to the Within Our Reach: Finding a Cure for Rheumatoid Arthritis campaign. Five years later, in November 2011, the REF launched the Journey to Cure campaign to raise $60 million—double the goal of the first campaign—and the ACR again was the first to step up, donating $5 million. This campaign will fund both the core award programs and the disease-targeted research grants.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

As we look forward to a new fundraising campaign, there is the strong sense in the organization that, at the same time we embark on the next prodigious goal, we are now also engaged in “business as usual,” because raising major funds to support training and research is what the REF does—and we do it very well.

We are excited to announce that the REF is poised to lead a new era of rheumatology support that focuses on advancing treatment and finding medical breakthroughs to cure rheumatic diseases. This year, the REF will fund nearly $12 million in fellowship training grants, career development awards, and disease-targeted research grants representing an incredible investment in innovative research and developing successful careers in rheumatology—both research and practice.

In September, the REF will—for the first time—fund $2 million in investigator-initiated clinical trials. This is a major step forward in our quest to advance treatment and find cures. Outcomes from these grants will lead to new insights into the treatment of rheumatoid arthritis (RA), answering questions about investigational drugs or looking at new ways of using known treatments relevant to RA. In addition to these clinical trials, the REF continues to fund $1.2 million in translational RA research as part of the highly successful Within Our Reach campaign.

Page: 1 2 3 | Single Page
Share: 

Filed under:Axial SpondyloarthritisCareer DevelopmentEducation & TrainingLegislation & AdvocacyPresident's PerspectiveProfessional TopicsResearch RheumRheumatoid Arthritis Tagged with:AC&RAdvocacyAmerican College of Rheumatology (ACR)Juvenile idiopathic arthritisResearchRheumatology Research Foundation

Related Articles

    A Look Back & A Look Ahead: ACR Research and Education Foundation Turns 25

    August 1, 2010

    The ACR Research and Education Foundation turns 25

    Rheumatology’s Architect

    March 1, 2008

    Help the REF lay foundations for our future

    Productive Partnership

    August 1, 2009

    The ACR and the REF work closely to support the future of rheumatology

    REF’s Campaign to Support RA Research Nears its Initial Funding Target

    September 1, 2010

    The REF’s campaign to support RA research nears its initial funding target

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences